DENTSPLY SIRONA's (XRAY) Hold Rating Reiterated at Needham & Company LLC

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report)'s stock had its "hold" rating reissued by equities researchers at Needham & Company LLC in a report released on Monday,Benzinga reports.

Several other research firms also recently issued reports on XRAY. Piper Sandler dropped their target price on DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Wall Street Zen raised DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research note on Sunday, July 13th. UBS Group cut their price objective on DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Barrington Research lifted their target price on shares of DENTSPLY SIRONA from $20.00 to $21.00 and gave the company an "outperform" rating in a report on Monday, May 12th. Finally, Morgan Stanley lowered shares of DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price objective for the company. in a report on Tuesday, April 15th. Ten research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $19.60.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock traded up $0.21 during trading on Monday, hitting $15.89. The company's stock had a trading volume of 2,886,563 shares, compared to its average volume of 2,906,152. The company has a market cap of $3.17 billion, a PE ratio of -3.49, a P/E/G ratio of 1.12 and a beta of 0.94. The company has a current ratio of 1.10, a quick ratio of 0.76 and a debt-to-equity ratio of 0.79. The business has a fifty day moving average of $16.07 and a 200-day moving average of $16.26. DENTSPLY SIRONA has a 52 week low of $12.16 and a 52 week high of $27.95.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.14. DENTSPLY SIRONA had a positive return on equity of 14.31% and a negative net margin of 24.42%. The business had revenue of $879.00 million during the quarter, compared to analyst estimates of $854.75 million. During the same period in the prior year, the company earned $0.42 earnings per share. DENTSPLY SIRONA's revenue was down 7.8% compared to the same quarter last year. As a group, research analysts anticipate that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in DENTSPLY SIRONA by 2.8% in the first quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier's stock valued at $309,864,000 after acquiring an additional 557,329 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in DENTSPLY SIRONA by 11.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier's stock valued at $208,590,000 after acquiring an additional 1,412,517 shares during the last quarter. Nuance Investments LLC lifted its holdings in DENTSPLY SIRONA by 25.0% in the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock valued at $257,103,000 after acquiring an additional 2,708,097 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in DENTSPLY SIRONA by 4.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier's stock valued at $180,445,000 after acquiring an additional 538,531 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in DENTSPLY SIRONA by 23.0% during the fourth quarter. Lazard Asset Management LLC now owns 8,044,228 shares of the medical instruments supplier's stock valued at $152,678,000 after buying an additional 1,505,928 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.